FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (2011)

Peer-Reviewed Study · Conroy T, Desseigne F, Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup · May 12, 2011

Conroy T et al., 2011-05-12: Phase 3 trial in 342 patients with metastatic pancreatic cancer comparing FOLFIRINOX with gemcitabine. Median overall survival was 11.1 versus 6.8 months, an advantage the authors describe as real but bought with increased toxicity.

The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001).

p.1817 (Abstract, Results)

Conroy T et al., 2011-05-12: Phase 3 trial in 342 patients with metastatic pancreatic cancer comparing FOLFIRINOX with gemcitabine. Median overall survival was 11.1 versus 6.8 months, an advantage the authors describe as real but bought with increased toxicity. Funder (abstract): 'the French government and others'; trial NCT00112658. No author disclosures appear in the MEDLINE record. Drugs are generic cytotoxics (oxaliplatin, irinotecan, leucovorin, fluorouracil); no manufacturer is named. Comparator: gemcitabine monotherapy, the then-standard first-line treatment, not placebo. For C1 the honest reading is split: relative benefit is large (HR 0.57) but absolute median survival stays under one year. Study type: randomized trial.